关键词： AH, alcohol-Associated hepatitis ALD, Alcohol-associated liver disease ASK-1, Apoptosis signal-regulating kinase-1 AUD, alcohol use disorder CCL2, C–C chemokine ligand type 2 CVC, Cenicriviroc ELAD, Extracorporeal liver assist device FMT, Fecal Microbiota Transplant G-CSF, Granulocyte colony-stimulating factor HA35, Hyaluronic Acid 35KD IL-1, interleukin 1 IL-6, interleukin 6 LCFA, saturated long-chain fatty acids LDL, low-density lipoprotein cholesterol LPS, Lipopolysaccharides MCP-1, monocyte chemoattractant protein −1 MDF, Maddrey's discriminant function MELD, Model for end-stage disease NAC, N-acetylcysteine NLRs, nucleotide-binding oligomerization domain-like receptors PAMPs, Pathogen-associated molecular patterns RCT, Randomized controlled trial SAM, S-Adenosyl methionine SCFA, short-chain fatty acids. 5 TLRs, Toll-like receptors TNF, tumor necrotic factor alcohol-associated hepatitis anti-inflammatory antioxidants liver-gut axis microbiome sAH, severe alcohol-associated hepatitis

来  源：   DOI：10.1016/j.jceh.2022.06.012   PDF(Pubmed)

Abstract：
The incidence of alcoholic-associated hepatitis (AH) is increasing. The treatment options for severe AH (sAH) are scarce and limited to corticosteroid therapy which showed limited mortality benefit in short-term use only. Therefore, there is a dire need for developing safe and effective therapies for patients with sAH and to improve their high mortality rates.This review article focuses on the current novel therapeutics targeting various mechanisms in the pathogenesis of alcohol-related hepatitis. Anti-inflammatory agents such as IL-1 inhibitor, Pan-caspase inhibitor, Apoptosis signal-regulating kinase-1, and CCL2 inhibitors are under investigation. Other group of agents include gut-liver axis modulators, hepatic regeneration, antioxidants, and Epigenic modulators. We describe the ongoing clinical trials of some of the new agents for alcohol-related hepatitis.
UNASSIGNED: A combination of therapies was investigated, possibly providing a synergistic effect of drugs with different mechanisms. Multiple clinical trials of novel therapies in AH remain ongoing. Their result could potentially make a difference in the clinical course of the disease. DUR-928 and granulocyte colony-stimulating factor had promising results and further trials are ongoing to evaluate their efficacy in the large patient sample.
摘要：
酒精相关性肝炎（AH）的发病率正在增加。严重AH（sAH）的治疗选择很少，并且仅限于皮质类固醇治疗，仅在短期使用时显示出有限的死亡率益处。因此,迫切需要为sAH患者开发安全有效的治疗方法,并提高其高死亡率.本文重点介绍了目前针对酒精相关性肝炎发病机理的各种机制的新型治疗方法。抗炎药如IL-1抑制剂，Pan-caspase抑制剂，凋亡信号调节激酶-1和CCL2抑制剂正在研究中。其他药物组包括肠-肝轴调节剂，肝再生，抗氧化剂,和表皮调节剂。我们描述了一些酒精相关肝炎新药的正在进行的临床试验。
未经批准：研究了多种疗法的组合，可能提供具有不同机制的药物的协同作用。AH新疗法的多项临床试验仍在进行中。他们的结果可能会对疾病的临床过程产生影响。DUR-928和粒细胞集落刺激因子具有可喜的结果，并且正在进行进一步的试验以评估其在大患者样本中的功效。
公众号